Special Issue

Viral Hepatitis in Brazil

Message from the Guest Editors

Viral hepatitis is a major global concern, as it contributes to the toll of deaths worldwide from infectious diseases and cancer. The five main types of hepatitis (A, B, C, D, and E) vary from transmission route, geographic distribution, and clinical outcome. Brazil is the sixth most populous country, has a diverse geographic distribution of these viruses and a diversity of countryspecific strains. In order to achieve the WHO goal of eliminating viral hepatitis by 2030, diagnostic investigation in the general Brazilian population has been intensified, mainly key high risk populations, to help identify and treat chronic carriers, , and prevent new infections. This Special Issue of the *Viruses* journal will address: 1) viral hepatitis genetic variations, which may assist in understanding diverse types of responses (clinical outcome, treatment, immunological) 2) epidemiological studies in general and key populations; and 3) new diagnostic procedures that will assist in the elimination of these viruses Dr. Lia Laura Lewis Ximenez de Souza Rodrigues Dr. Livia Melo Villar

Guest Editors

Dr. Lia L. Lewis-Ximenez

Viral Hepatitis Ambulatory, Viral Hepatitis Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brazil

Dr. Livia Melo Villar

Viral Hepatitis Laboratory, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brazil

Deadline for manuscript submissions

closed (15 December 2022)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/101447

Viruses

MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.1 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2024).